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Breast cancer is the most common cancer among women and the second most common cancer in 
the world. It is a leading public health problem, with over one million new cases and 459,000 
related deaths annually. Studies have revealed the importance of differential biochemical 
parameters and glucose metabolism in the development of critical biomarkers for accurate 
diagnosis and treatment of breast cancer. Forestalling the heavy burden of breast cancer is 
predicated upon the delineation of its related biomarkers hence the aim of this study which was 
to assess the biochemical parameters and expression and methylation of Hexokinase II gene of 
breast cancer patients in Nigeria. In this line of investigation, using standard methods, the 
expression and methylation of hexokinase II and some biochemical parameters including 
Alanine transaminase (ALT), Aspartate transaminase (AST), Alkaline phosphatase (ALP), Low 
density lipoprotein (LDL), High density lipoprotein (HDL) and triglycerides (TRIG) were 
examined in the plasma of 50 breast cancer patients attending the cancer clinic of Lagos State 
University Teaching Hospital (LASUTH) and 10 healthy control subjects. Students T-test was 
used to compare the test and control samples with (P<0.05) considered as significant. The data 
obtained indicates that there were no significant (P<0.05) differences in the AST, ALP, LDL and 
TRIG while there was a significant difference in the values of ALT (0.166±0.019U/L) and HDL 
(48.042±5.737mg/dL). There was also a significantly higher expression of Hexokinase II in the 
breast cancer patients. The hexokinase gene of the breast cancer patients were seen to be 
unmethylated as opposed to the control which were methylated. The data obtained from this 
study indicates the possible implication of ALT and HDL in breast cancer disease in Nigeria and 
their potential to be further developed into biomarkers for diagnosis of the disease. Also, the 
significant expression and unmethylation of Hexokinase II shows its possible association with 
breast cancer progression in Nigerian patients. The findings from this study provide a deeper 
understanding of breast cancer and a wider scope for improvement in the diagnosis and 
management of the disease. 
